专栏咏竹坊

With no cure in sight, drugs firm LianBio begins exit strategy

The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four years after being founded.

By Molly Wen

LianBio (LIAN.US) was a rising star of the Chinese pharmaceutical scene but the drugs startup has flamed out just four years after its launch.

The biotech’s abbreviated lifespan underscores the challenges and costs of bringing novel drugs to the market, even with financial backing and big ambitions.

您已阅读5%(311字),剩余95%(5496字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×